Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod in Diabetic Gastropathy
NCT00142974Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tegaserod in diabetic gastropathy (3 arms), sponsored by Novartis. Primary endpoint: Diabetic Gastropathy Dyspeptic Symptom Severity Score at 6 weeks. Started May 2004; status: terminated.
02
Drugs
tegaserod
03
Conditions
diabetic gastropathy
Beyond the preview
Go deeper on NCT00142974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142974.